Posted On: 12/28/2016 12:07:18 AM
Post# of 30066
.jpg)
Herantis is the Finnish company owning CDNF
MANF/CDNF symposium still happening end of january
interestingly enough they're going to start a Parkinsons clinical trial first half of 2017, using Renishaw's delivery mechanism, just like we would. Allegedly MANF and CDNF work best paired together. Perhaps promise in their trials will get juices going toward our trials. They just got a $6mill Euro grant for the trial from EU.
stock has tripled since summer, currently about 3euro, though down since companies founding. MC 12-13mill Euro
latest presentation http://herantis.com/wp-content/uploads/2016/1...-12-01.pdf
http://herantis.com/pipeline/cdnf-in-parkinsons-disease/
Saarma on board along with prior Roche/genentech Knowles,
MANF/CDNF symposium still happening end of january
interestingly enough they're going to start a Parkinsons clinical trial first half of 2017, using Renishaw's delivery mechanism, just like we would. Allegedly MANF and CDNF work best paired together. Perhaps promise in their trials will get juices going toward our trials. They just got a $6mill Euro grant for the trial from EU.
stock has tripled since summer, currently about 3euro, though down since companies founding. MC 12-13mill Euro
latest presentation http://herantis.com/wp-content/uploads/2016/1...-12-01.pdf
http://herantis.com/pipeline/cdnf-in-parkinsons-disease/
Saarma on board along with prior Roche/genentech Knowles,
(2)
(0)
